Literature DB >> 153773

Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma.

D Collen, B Wiman.   

Abstract

Human antiplasmin, the fast-acting plasmin inhibitor in plasma, was purified to homogeneity and labeled with 125I. This material, which was indistinguishable from antiplasmin in plasma with respect to several physicochemical and functional properties, was injected intravenously and its turnover measured in control subjects and in patients undergoing thrombolytic therapy. In eight control subjects (four healthy persons and four patients with atherosclerosis), the following turnover characteristics were obtained: plasma radioactivity half-life 2.64 +/- 0.32 days, fractional catabolic rate 0.53 +/- 0.09 of the plasma pool per day, intravascular fraction 0.51 +/- 0.05, and synthetic (catabolic) rate 1.4 +/- 0.27 mg/kg/day. The half-life of the plasmin-antiplasmin complex in plasma, measured from the disappearance rate of labeled antiplasmin, plasmin or plasmin-antiplasmin complex during thrombolytic therapy was approximately 0.5 days.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 153773

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

Review 2.  α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.

Authors:  Guy L Reed; Aiilyan K Houng; Satish Singh; Dong Wang
Journal:  Semin Thromb Hemost       Date:  2016-07-29       Impact factor: 4.180

Review 3.  Natural inhibitors of fibrinolysis.

Authors:  D Collen
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

Review 4.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

5.  Structural and functional characterization of cleavage and inactivation of human serine protease inhibitors by the bacterial SPATE protease EspPα from enterohemorrhagic E. coli.

Authors:  André Weiss; Hanna Joerss; Jens Brockmeyer
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

Review 6.  Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

Authors:  Nikoletta Pechlivani; Katherine J Kearney; Ramzi A Ajjan
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

Review 7.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

8.  Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum Transfusion.

Authors:  Heiko Rühl; Christina Berens; Anna Winterhagen; Jens Müller; Johannes Oldenburg; Bernd Pötzsch
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

9.  Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.

Authors:  Wenrui Hao; Avner Friedman
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

10.  Computational Simulations of Thrombolytic Therapy in Acute Ischaemic Stroke.

Authors:  Andris Piebalgs; Boram Gu; Dylan Roi; Kyriakos Lobotesis; Simon Thom; Xiao Yun Xu
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.